Clinical Trials
Medigene receives approvals for its first clinical trial with TCR therapy MDG1011
Medigene AG announced that the German Senior Federal Authority "Paul-Ehrlich-Institute" (PEI) and the relevant ethics committee have approved the study design of the first...
Press Releases
Allergan Presents Data at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego
The meeting will be held at the San Diego Convention Center and the scheduled times (noted in local Pacific Time) for the Allergan presentations,...
Clinical Trials
Vertex announces positive results of phase 2 study of Nav1.8 inhibitor VX -150 for Acute pain
Vertex Pharmaceuticals Inc announced positive results of a Phase 2 study of the NaV1.8 inhibitor VX-150 in patients with acute pain following bunionectomy surgery....
Clinical Trials
OTEZLA® (Apremilast) Phase II Data Showed Clinically significant Improvements in Patients with Active Ulcerative Colitis
Celgene Corporation announced that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had...
Clinical Trials
OTEZLA (Apremilast) Phase III Data Showed good results among Patients with Active Behçet’s Disease with Oral Ulcers
Celgene Corporation announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet's Disease with oral ulcers...
News
Bristol-Myers Squibb and Nektar Therapeutics to collaborate for Nektar’s CD122-biased Agonist, NKTR-214
Bristol-Myers Squibb Company announced the companies have executed a global strategic development and commercialization collaboration for Nektar’s lead immuno-oncology program, NKTR-214. ...
White Papers
Process Considerations for Cryogenic and Regenerative Medicine Commercialization
McKesson, Fisher BioServices, GE Healthcare and Cryoport are proud to announce our first annual workshop. Our FREE two-day workshop will provide a forum for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read